Embecta's (EMBC) "Hold (C-)" Rating Reiterated at Weiss Ratings

Key Points

• Embecta's stock has received a "hold (C-)" rating from Weiss Ratings, while other analysts have mixed opinions with ratings ranging from "strong-buy" to "neutral."
• The company's recent earnings report indicated strong performance, with an EPS of $1.12, exceeding expectations and marking an 8.4% revenue growth year-over-year.
• Institutional investors hold a significant share of Embecta, owning 93.83% of the company's stock, indicating strong interest in the company.

Embecta (NASDAQ:EMBC - Get Free Report)'s stock had its "hold (c-)" rating reiterated by analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently commented on the stock. Wall Street Zen upgraded shares of Embecta from a "buy" rating to a "strong-buy" rating in a research report on Saturday, August 16th. BTIG Research restated a "buy" rating and issued a $25.00 target price on shares of Embecta in a report on Friday, September 5th. Mizuho dropped their target price on shares of Embecta from $13.00 to $12.00 and set a "neutral" rating on the stock in a report on Wednesday, July 16th. Finally, Zacks Research upgraded shares of Embecta from a "hold" rating to a "strong-buy" rating in a report on Tuesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $19.00.

Embecta Trading Up 0.3%

NASDAQ:EMBC traded up $0.04 during mid-day trading on Wednesday, hitting $13.82. 345,872 shares of the company's stock were exchanged, compared to its average volume of 496,682. The company has a 50 day simple moving average of $13.77 and a 200-day simple moving average of $12.06. Embecta has a fifty-two week low of $9.20 and a fifty-two week high of $21.48. The firm has a market capitalization of $808.26 million, a P/E ratio of 9.66, a PEG ratio of 0.76 and a beta of 1.10.

Embecta (NASDAQ:EMBC - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported $1.12 EPS for the quarter, topping the consensus estimate of $0.77 by $0.35. Embecta had a net margin of 7.58% and a negative return on equity of 23.40%. The business had revenue of $295.50 million for the quarter, compared to the consensus estimate of $278.15 million. During the same period last year, the company earned $0.74 EPS. The firm's revenue was up 8.4% compared to the same quarter last year. Embecta has set its FY 2025 guidance at 2.900-2.950 EPS. As a group, analysts expect that Embecta will post 2.85 earnings per share for the current year.

Institutional Trading of Embecta

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC raised its holdings in shares of Embecta by 103.6% in the second quarter. Squarepoint Ops LLC now owns 403,412 shares of the company's stock valued at $3,909,000 after purchasing an additional 205,311 shares during the last quarter. Public Sector Pension Investment Board lifted its holdings in Embecta by 8.1% during the second quarter. Public Sector Pension Investment Board now owns 199,227 shares of the company's stock valued at $1,931,000 after purchasing an additional 14,908 shares during the last quarter. Tower Research Capital LLC TRC lifted its holdings in Embecta by 542.6% during the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company's stock valued at $71,000 after purchasing an additional 6,224 shares during the last quarter. Man Group plc lifted its holdings in Embecta by 25.6% during the second quarter. Man Group plc now owns 36,002 shares of the company's stock valued at $349,000 after purchasing an additional 7,339 shares during the last quarter. Finally, Humankind Investments LLC purchased a new stake in Embecta during the second quarter valued at about $111,000. Institutional investors own 93.83% of the company's stock.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.